Stablix logo

Stablix

New York, NY

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The company’s resorted platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer, and immunological disorders.

stablix.com

Company Details

Founded

2021

Employees

Between 20 - 100 employees

Raised

$63,000,000

Headquarters Location

New York, NY

Public

No

Acquired

No

CEO

Tony KingsleyTony Kingsley

Founders

Brian Bowman
Henry Colecraft
Henry Colecraft
Scott Kanner
Scott Kanner
Carlo Rizzuto
Carlo Rizzuto
Kevin Sprott
Kevin Sprott

Company Collections

These are collections Stablix is a part of. Click on the collection name to view similar companies.